You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals
|
|---|---|
| Published in |
Cardiovascular Diabetology, March 2013
|
| DOI | 10.1186/1475-2840-12-48 |
| Pubmed ID | |
| Authors |
Alison R Meloni, Mary Beth DeYoung, Jenny Han, Jennie H Best, Michael Grimm |
| Abstract |
Diabetes is associated with a higher risk for adverse cardiovascular outcomes. To improve the health outcomes of patients with type 2 diabetes (T2DM), the American Diabetes Association (ADA) recommended target goals for the improvement of glycemic control and the reduction of cardiovascular risk factors associated with the disease. This retrospective analysis calculated the absolute benefit increase (ABI) of using exenatide once weekly (QW), a glucagon-like peptide-1 (GLP-1) receptor agonist, vs an oral glucose-lowering medication or insulin glargine to achieve ADA-recommended goals. The number needed to treat (NNT) to achieve these goals was also calculated and provides a useful clinical metric for comparing potential therapies from different drug classes. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 141 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | <1% |
| Spain | 1 | <1% |
| Denmark | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 137 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 22 | 16% |
| Student > Master | 19 | 13% |
| Student > Postgraduate | 14 | 10% |
| Researcher | 12 | 9% |
| Other | 11 | 8% |
| Other | 29 | 21% |
| Unknown | 34 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 58 | 41% |
| Nursing and Health Professions | 11 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 6% |
| Unspecified | 6 | 4% |
| Agricultural and Biological Sciences | 5 | 4% |
| Other | 15 | 11% |
| Unknown | 38 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 April 2013.
All research outputs
#15,268,549
of 22,705,019 outputs
Outputs from Cardiovascular Diabetology
#825
of 1,366 outputs
Outputs of similar age
#123,697
of 197,511 outputs
Outputs of similar age from Cardiovascular Diabetology
#6
of 14 outputs
Altmetric has tracked 22,705,019 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,366 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.7. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 197,511 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.